Arete Wealth Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $294K | Hold |
13,625
| – | – | 0.02% | 566 |
|
|
2025
Q1 | $226K | Sell |
13,625
-75
| -0.5% | -$1.24K | 0.02% | 631 |
|
|
2024
Q4 | $251K | Buy |
13,700
+1,875
| +16% | +$34.4K | 0.02% | 615 |
|
|
2024
Q3 | $182K | Sell |
11,825
-3,875
| -25% | -$59.6K | 0.02% | 661 |
|
|
2024
Q2 | $255K | Sell |
15,700
-300
| -2% | -$4.87K | 0.02% | 573 |
|
|
2024
Q1 | $296K | Buy |
+16,000
| New | +$296K | 0.03% | 346 |
|
|
2023
Q4 | – | Sell |
-16,600
| Closed | -$346K | – | 743 |
|
|
2023
Q3 | $346K | Buy |
16,600
+3,950
| +31% | +$82.3K | 0.06% | 316 |
|
|
2023
Q2 | $303K | Sell |
12,650
-4,250
| -25% | -$102K | 0.03% | 495 |
|
|
2023
Q1 | $318K | Sell |
16,900
-378
| -2% | -$7.11K | 0.03% | 456 |
|
|
2022
Q4 | $275M | Buy |
+17,278
| New | +$275M | 0.02% | 478 |
|